XML 38 R25.htm IDEA: XBRL DOCUMENT
v3.23.3

SIGNIFICANT ACCOUNTING POLICIES (Details) $ / shares in Units, $ in Thousands |  |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Feb. 27, 2023 USD ($) | Aug. 29, 2022 | Jul. 02, 2021 USD ($) $ / shares shares | May 13, 2021 USD ($) | Jul. 23, 2018 USD ($) | Oct. 19, 2017 USD ($) | Oct. 31, 2015 | Sep. 30, 2023 USD ($) agreement $ / shares shares | Mar. 31, 2023 USD ($) shares | Sep. 30, 2023 USD ($) agreement $ / shares shares | Sep. 30, 2022 USD ($) | Mar. 21, 2023 item | Dec. 31, 2022 $ / shares
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of global licensing and supply agreements | agreement |  |  |  |  |  |  |  | 2 |  | 2 |  |  |
Number of patients dosed | item |  |  |  |  |  |  |  |  |  |  |  | 32 |
Common Stock, Par or Stated Value Per Share | $ / shares |  |  |  |  |  |  |  | $ 0.001 |  | $ 0.001 |  |  | $ 0.001
Stock issuance proceeds |  |  |  |  |  |  |  |  |  | $ 23,954 | $ 4,161 |  |
Convertible Debt, Current |  |  |  |  |  |  |  | $ 20,192 |  | 20,192 |  |  |
ATM Shares |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares issued (in shares) | shares |  |  |  |  |  |  |  |  | 13,980,060 |  |  |  |
Common Stock, Par or Stated Value Per Share | $ / shares |  |  | $ 0.001 |  |  |  |  |  |  |  |  |  |
Sale of stock, maximum offering price | $ 20,000 |  | $ 20,000 |  |  |  |  |  |  | $ 6,400 |  |  |
Stock issuance proceeds |  |  |  |  |  |  |  |  | $ 20,000 |  |  |  |
ATM Equity Offering Sales Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares issued (in shares) | shares |  |  | 3,296,123 |  |  |  |  | 0 |  | 12,560,150 |  |  |
Stock issuance proceeds |  |  | $ 13,800 |  |  |  |  |  |  | $ 24,900 |  |  |
2024 Notes |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Interest rate (as a percent) |  |  |  |  |  |  |  | 7.50% |  | 7.50% |  |  |
Maintain of Minimum Cash Balance |  |  |  |  |  |  |  | $ 7,500 |  | $ 7,500 |  |  |
Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement Revenues and Expenses Sharing Percentage |  |  |  |  |  |  | 100.00% |  |  |  |  |  |
Chiesi Agreements |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Amount of milestone payment received |  |  |  |  |  |  |  |  |  | $ 20,000 |  |  |
Revenue, Performance Obligation, Number | agreement |  |  |  |  |  |  |  | 2 |  | 2 |  |  |
Chiesi US Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Additional Amounts Payable To Cover Development Costs |  |  |  |  | $ 20,000 |  |  |  |  |  |  |  |
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones |  |  |  |  | $ 760,000 |  |  |  |  |  |  |  |
Chiesi US Agreement | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Payment On Net Sales Percentage |  |  |  |  | 15.00% |  |  |  |  |  |  |  |
Chiesi US Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Payment On Net Sales Percentage |  |  |  |  | 40.00% |  |  |  |  |  |  |  |
Chiesi Ex-US Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Additional Amounts Payable To Cover Development Costs |  |  |  |  |  | $ 25,000 |  |  |  |  |  |  |
Agreement Amendment Payment Receivable |  |  |  | $ 10,000 |  |  |  |  |  |  |  |  |
Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones |  |  |  | $ 25,000 |  |  |  |  |  |  |  |  |
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones |  |  |  |  |  | $ 320,000 |  |  |  |  |  |  |
Chiesi Ex-US Agreement | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Payment On Net Sales Percentage |  |  |  |  |  | 15.00% |  |  |  |  |  |  |
Chiesi Ex-US Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Payment On Net Sales Percentage |  |  |  |  |  | 35.00% |  |  |  |  |  |  |
Fill/Finish Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Extended term of agreement |  | 7 years |  |  |  |  |  |  |  |  |  |  |
Chiesi US Agreement and Chiesi Ex-US Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable Payment Receivable |  |  |  |  | $ 25,000 | $ 25,000 |  |  |  |  |  |  |

X
- Definition The total amount payable to entity for the achievement of regulatory and commercial milestones. + References No definition available. + Details
Name: | plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount payable to the entity to cover development costs under agreement. + References No definition available. + Details
Name: | plx_AdditionalAmountsPayableToCoverDevelopmentCosts
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Agreement Amendment Payment Receivable + References No definition available. + Details
Name: | plx_AgreementAmendmentPaymentReceivable
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones + References No definition available. + Details
Name: | plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative arrangement revenues and expense sharing percentage. + References No definition available. + Details
Name: | plx_CollaborativeArrangementRevenuesExpensesSharingPercentage
Namespace Prefix: | plx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Extended term of agreement. + References No definition available. + Details
Name: | plx_ExtendedTermOfAgreement
Namespace Prefix: | plx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum cash balance required to be maintained under long term debt agreements. + References No definition available. + Details
Name: | plx_MaintainOfMinimumCashBalance
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of milestone payment received upon achievement of certain milestone. + References No definition available. + Details
Name: | plx_MilestonePaymentReceived
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the number of global licensing and supply agreements. + References No definition available. + Details
Name: | plx_NumberOfGlobalLicensingAndSupplyAgreements
Namespace Prefix: | plx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the number of patients that were dosed in the trial. + References No definition available. + Details
Name: | plx_NumberOfPatientsDosed
Namespace Prefix: | plx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the payment as a percentage of future net sales. + References No definition available. + Details
Name: | plx_PaymentOnNetSalesPercentage
Namespace Prefix: | plx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Performance Obligation, Number + References No definition available. + Details
Name: | plx_RevenuePerformanceObligationNumber
Namespace Prefix: | plx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Sale of stock, maximum offering price. + References No definition available. + Details
Name: | plx_SaleOfStockMaximumOfferingPrice
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | plx_SignificantAccountingPoliciesLineItems
Namespace Prefix: | plx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights. + References No definition available. + Details
Name: | plx_UpfrontNonrefundableNoncreditablePaymentReceivable
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_ConvertibleDebtCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contractual interest rate for funds borrowed, under the debt agreement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1B -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_BR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |